Bibliographic Details
| Title: |
Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques |
| Authors: |
Bryce M. Warner, Mable Chan, Nikesh Tailor, Robert Vendramelli, Jonathan Audet, Courtney Meilleur, Thang Truong, Lauren Garnett, Marnie Willman, Geoff Soule, Kevin Tierney, Alixandra Albietz, Estella Moffat, Rick Higgins, Lisa A. Santry, Alexander Leacy, Phuc H. Pham, Jacob G. E. Yates, Yanlong Pei, David Safronetz, James E. Strong, Leonardo Susta, Carissa Embury-Hyatt, Sarah K. Wootton, Darwyn Kobasa |
| Source: |
Vaccines, Vol 12, Iss 4, p 404 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
Newcastle disease virus, SARS-CoV-2, COVID-19, vaccine, cynomolgus macaque, Medicine |
| More Details: |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged following an outbreak of unexplained viral illness in China in late 2019. Since then, it has spread globally causing a pandemic that has resulted in millions of deaths and has had enormous economic and social consequences. The emergence of SARS-CoV-2 saw the rapid and widespread development of a number of vaccine candidates worldwide, and this never-before-seen pace of vaccine development led to several candidates progressing immediately through clinical trials. Many countries have now approved vaccines for emergency use, with large-scale vaccination programs ongoing. Despite these successes, there remains a need for ongoing pre-clinical and clinical development of vaccine candidates against SARS-CoV-2, as well as vaccines that can elicit strong mucosal immune responses. Here, we report on the efficacy of a Newcastle disease virus-vectored vaccine candidate expressing SARS-CoV-2 spike protein (NDV-FLS) administered to cynomolgus macaques. Macaques given two doses of the vaccine via respiratory immunization developed robust immune responses and had reduced viral RNA levels in nasal swabs and in the lower airway. Our data indicate that NDV-FLS administered mucosally provides significant protection against SARS-CoV-2 infection, resulting in reduced viral burden and disease manifestation, and should be considered as a viable candidate for clinical development. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2076-393X |
| Relation: |
https://www.mdpi.com/2076-393X/12/4/404; https://doaj.org/toc/2076-393X |
| DOI: |
10.3390/vaccines12040404 |
| Access URL: |
https://doaj.org/article/5e4cccc3f31e4e15bd81f344156fe762 |
| Accession Number: |
edsdoj.5e4cccc3f31e4e15bd81f344156fe762 |
| Database: |
Directory of Open Access Journals |
